Serum Lipids and Lipokines as Prognostic/Diagnostic Biomarkers in Common Cancers

作     者：Nikolaos Dogkas Maria Τrapali Christine Fountzoula Georgios Albert Karikas Petros Karkalousos Nikolaos Dogkas;Maria Τrapali;Christine Fountzoula;Georgios Albert Karikas;Petros Karkalousos

作者机构：Biochemistry Laboratory General Anticancer Hospital of Piraeus “METAXA” Piraeus Greece Department of Biomedical Sciences School of Health and Care Sciences University of West Attica Athens Greece 

出 版 物：《Journal of Diabetes Mellitus》 (糖尿病（英文）)

年 卷 期：2022年第12卷第2期

页      面：122-140页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Cancer Total Cholesterol Triglycerides HDL LDL Resistin Visfatin 

摘      要：Total cholesterol (CHOL) levels have been shown in many studies, to be higher in people with several types of cancer. Similar results are observed for both triglycerides (TG) and low-density cholesterol (LDL), as opposed to high-density cholesterol (HDL). Chemotherapy seems to reduce CHOL and LDL, leading to a reduction. Furthermore, the recurrence of high levels of CHOL, TG and LDL, as well as low levels of HDL, after receiving treatment, or when patients appear to have been cured, are signs of a possible recurrence of the disease. Lipoprotein α (Lpa), occurs at higher levels in patients than in healthy people, whereas lipokines resistin and bisfatin, “hormonal products of adipose tissue exhibited high levels in cancer cases, compared to control groups.